Zobrazeno 1 - 10
of 200
pro vyhledávání: '"Shuichi, Hironaka"'
Autor:
Naoki Takahashi, Hiroki Hara, Kengo Nagashima, Kenro Hirata, Toshiki Masuishi, Toshihiko Matsumoto, Hisato Kawakami, Kentaro Yamazaki, Shuichi Hironaka, Narikazu Boku, Kei Muro
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-8 (2023)
Abstract Background Trifluridine/tipiracil (FTD/TPI) prolongs survival in the third- or later-line treatment for advanced gastric cancer (GC), esophagogastric junction (EGJ) adenocarcinoma, and colorectal cancer. While single-arm phase II trials show
Externí odkaz:
https://doaj.org/article/7e4e091163904bb1a0330ed3bafd6354
Autor:
Kenro Hirata, Yasuo Hamamoto, Masahiko Ando, Chiyo K. Imamura, Kenichi Yoshimura, Kentaro Yamazaki, Shuichi Hironaka, Kei Muro
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-7 (2020)
Abstract Background Ramucirumab (RAM) with weekly paclitaxel (wPTX) is a standard second-line therapy for advanced or recurrent gastric cancer. Nanoparticle albumin-bound paclitaxel (nab-PTX), an albumin-bound form of PTX, was developed to improve th
Externí odkaz:
https://doaj.org/article/a332fc43772e4bc28958927b98d34bc2
Autor:
Hiroyuki Arai, Satoru Iwasa, Narikazu Boku, Masahiro Kawahira, Hirofumi Yasui, Toshiki Masuishi, Kei Muro, Keiko Minashi, Shuichi Hironaka, Naoki Fukuda, Daisuke Takahari, Takako Eguchi Nakajima
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-11 (2019)
Abstract Background There is no standard first-line chemotherapy for advanced gastric cancer with severe peritoneal metastasis. Although fluoropyrimidine is often used, its efficacy is limited, and it remains unclear whether combination therapy with
Externí odkaz:
https://doaj.org/article/84fcec85faaf40e8956c431946702505
Autor:
Hiroya Taniguchi, Wataru Okamoto, Kei Muro, Kiwamu Akagi, Hiroki Hara, Tomohiro Nishina, Takeshi Kajiwara, Tadamichi Denda, Shuichi Hironaka, Toshihiro Kudo, Taroh Satoh, Takeharu Yamanaka, Yukiko Abe, Yoshiyuki Fukushima, Takayuki Yoshino
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 20, Iss 12, Pp 1219-1226 (2018)
Detection of RAS and BRAF mutations is essential to determine the optimal treatment strategy for metastatic colorectal cancer (CRC). We prospectively evaluated the MEBGEN RASKET-B KIT (RASKET-B), a novel multiplex kit, simultaneously detecting 48 typ
Externí odkaz:
https://doaj.org/article/9de1b05e08994b4bb0fcc4a33b6939b3
Autor:
Keitaro Shimozaki, Kenro Hirata, Taro Sato, Maho Nakamura, Kyoko Kato, Hidekazu Hirano, Yosuke Kumekawa, Kaori Hino, Kentaro Kawakami, Yosuke Kito, Toshihiko Matsumoto, Takeshi Kawakami, Masato Komoda, Kengo Nagashima, Yasunori Sato, Kentaro Yamazaki, Shuichi Hironaka, Hiromasa Takaishi, Yasuo Hamamoto, Kei Muro
Publikováno v:
Clinical Colorectal Cancer. 21:339-346
Autor:
Takashi Ura, Shuichi Hironaka, Yasuhiro Tsubosa, Junki Mizusawa, Ken Kato, Takahiro Tsushima, Kunihiro Fushiki, Keisho Chin, Akihisa Tomori, Tatsuya Okuno, Hisayuki Matsushita, Takashi Kojima, Yuichiro Doki, Hitoshi Kusaba, Kazumasa Fujitani, Shiko Seki, Yuko Kitagawa
Publikováno v:
Esophagus. 20:272-280
We herein investigated the association between early tumor shrinkage (ETS) and depth of response (DpR) and clinical outcomes in patients with metastatic esophageal cancer treated with 2-weekly docetaxel combined with cisplatin plus fluorouracil (bDCF
Autor:
Hiroya, Takeuchi, Yoshinori, Ito, Ryunosuke, Machida, Ken, Kato, Masakatsu, Onozawa, Keiko, Minashi, Tomonori, Yano, Kenichi, Nakamura, Takahiro, Tsushima, Hiroki, Hara, Tatsuya, Okuno, Shuichi, Hironaka, Isao, Nozaki, Takashi, Ura, Keisho, Chin, Takashi, Kojima, Shiko, Seki, Katsuyuki, Sakanaka, Haruhiko, Fukuda, Yuko, Kitagawa
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 114:454-462
Definitive chemoradiotherapy (CRT) is the standard treatment for patients with locally advanced esophageal cancer (EC) who refuse surgery as the initial therapy. However, poor survival, a high incidence of late toxicities, and severe complications af
Autor:
Kei Muro, Kohei Shitara, Kensei Yamaguchi, Takaki Yoshikawa, Hironaga Satake, Hiroki Hara, Naotoshi Sugimoto, Nozomu Machida, Masahiro Goto, Hisato Kawakami, Kenji Amagai, Yasushi Omuro, Taito Esaki, Shuichi Hironaka, Tomohiro Nishina, Yoshito Komatsu, Hisahiro Matsubara, Shinichi Shiratori, Shirong Han, Taroh Satoh, Atsushi Ohtsu
Publikováno v:
Journal of Gastrointestinal Cancer.
Purpose Pembrolizumab demonstrated antitumor activity in programmed death ligand 1 positive (combined positive score (CPS) ≥ 1) gastric/gastroesophageal junction cancer in KEYNOTE-059 (third line or beyond), KEYNOTE-061 (second line), and KEYNOTE-0
Autor:
Charles S. Fuchs, David Ferry, Ling Gao, Allen S. Melemed, Lan Ni, Azhar Khan, Michael Heathman, Yanzhi Hsu, Kumari Chandrawansa, Howard Safran, Jiri Tomasek, Jaffer A. Ajani, Shuichi Hironaka, Yasuhiro Shimada, György Bodoky, Sang Cheul Oh, Eric Van Cutsem, Kei Muro, Atsushi Ohtsu, Josep Tabernero
Ramucirumab is an IgG1 monoclonal antibody specific for the vascular endothelial growth factor receptor-2. Ramucirumab, 8 mg/kg every 2 weeks, administered as monotherapy (REGARD) or in combination with paclitaxel (RAINBOW), was safe and effective in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fa5b36e715805f8c083550fe760165db
https://doi.org/10.1158/1535-7163.c.6538746.v1
https://doi.org/10.1158/1535-7163.c.6538746.v1
Autor:
Charles S. Fuchs, David Ferry, Ling Gao, Allen S. Melemed, Lan Ni, Azhar Khan, Michael Heathman, Yanzhi Hsu, Kumari Chandrawansa, Howard Safran, Jiri Tomasek, Jaffer A. Ajani, Shuichi Hironaka, Yasuhiro Shimada, György Bodoky, Sang Cheul Oh, Eric Van Cutsem, Kei Muro, Atsushi Ohtsu, Josep Tabernero
Figure S1 shows the predicted ramucirumab concentration (μg/mL) over an 8-mg/kg dosing regimen to predicted steady-state.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::374fd6ca7ca6e4d280a1be0072efc94a
https://doi.org/10.1158/1535-7163.22507644
https://doi.org/10.1158/1535-7163.22507644